Topadur Pharma

News

8.9.22

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR Pharma AG has been selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team, supporters, and partners believing in us along the way!

Please check out the link below.

‍

Download Document Dokument herunterladen https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022 https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022

27.5.21

News

Innosuisse innovation project starting May 2021

TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.

15.10.21

Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

5.10.21

Press Release

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

Innosuisse innovation project starting May 2021

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

Investors

About us

Pipeline

Contact